Payment overview · 2025
General Payments
$3,824.15
158 reported records · 37 companies
Healthcare provider profile · identity verified
David D Edalati, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OVERLAND PARK, KS · NPI 1477669141
Verified facts
What the public records show
CMS Open Payments records show David D Edalati, MD received $3,824.15 in general payments during 2025 across 158 reported records.
Axsome Therapeutics, Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Belbuca by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $435.90 | 11.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $343.80 | 9.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $322.48 | 8.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $308.71 | 8.1% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $265.00 | 6.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $245.91 | 6.4% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $183.28 | 4.8% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.29 | 4.6% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $152.61 | 4.0% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $131.91 | 3.5% | 2 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $118.80 | 3.1% | 6 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $115.25 | 3.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $98.47 | 2.6% | 5 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.04 | 2.4% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $73.76 | 1.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.04 | 1.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.50 | 1.6% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $57.53 | 1.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.96 | 1.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.27 | 1.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.79 | 1.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.42 | 1.1% | 2 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $42.03 | 1.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.39 | 1.1% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $39.28 | 1.0% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $32.86 | 0.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.29 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.77 | 0.7% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $24.88 | 0.7% | 1 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $24.32 | 0.6% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $24.03 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.28 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.14 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.4% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $14.24 | 0.4% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.57 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,806.77 | 157 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $274.86 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $241.41 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $235.24 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.95 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $183.28 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $176.29 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $168.59 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $162.66 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $161.04 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $152.61 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $147.93 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $139.13 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $134.26 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $131.91 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.71 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $118.80 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $117.07 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $115.25 | 4 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $99.17 | 5 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $99.17 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $98.47 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.99 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.30 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $78.60 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.68 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.04 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.04 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.50 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $57.53 | 3 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $51.02 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.96 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.27 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.79 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.41 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 225 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 547 | 102 |
| Omeprazole | Omeprazole | 441 | 101 |
| Gabapentin | Gabapentin | 426 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 423 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 404 | 70 |
| Montelukast Sodium | Montelukast Sodium | 377 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 354 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 91 |
| Potassium Chloride | Potassium Chloride | 306 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 55 |
| Tramadol Hcl | Tramadol Hcl | 282 | 35 |
| Losartan Potassium | Losartan Potassium | 277 | 56 |
| Metformin Hcl | Metformin Hcl | 274 | 66 |
| Lisinopril | Lisinopril | 252 | 52 |
| Famotidine | Famotidine | 235 | 30 |
| Eliquis | Apixaban | 225 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 219 | 29 |
| Trazodone Hcl | Trazodone Hcl | 219 | 52 |
| Sertraline Hcl | Sertraline Hcl | 215 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 74 |
| Carvedilol | Carvedilol | 182 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 27 |
| Lorazepam | Lorazepam | 177 | 25 |
| Donepezil Hcl | Donepezil Hcl | 171 | 27 |
| Furosemide | Furosemide | 161 | 33 |
| Ozempic | Semaglutide | 158 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 32 |
| Alprazolam | Alprazolam | 155 | 26 |
| Memantine Hcl | Memantine Hcl | 151 | 17 |
| Pregabalin | Pregabalin | 136 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 22 |
| Meloxicam | Meloxicam | 128 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 123 | 82 |
| Mirtazapine | Mirtazapine | 123 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 112 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 23 |
| Metformin Hcl Er | Metformin Hcl | 103 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 27 |
| Celecoxib | Celecoxib | 99 | 24 |
| Simvastatin | Simvastatin | 98 | 23 |
| Farxiga | Dapagliflozin Propanediol | 97 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 13 |
| Prednisone | Prednisone | 95 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 94 | 11 |
| Xarelto | Rivaroxaban | 94 | 11 |
| Cefuroxime | Cefuroxime Axetil | 92 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 25 |
| Spironolactone | Spironolactone | 90 | 12 |
| Allopurinol | Allopurinol | 88 | 20 |
| Torsemide | Torsemide | 88 | 12 |
| Clonazepam | Clonazepam | 86 | 13 |
| Jardiance | Empagliflozin | 83 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 21 |
| Buspirone Hcl | Buspirone Hcl | 79 | 18 |
| Levetiracetam | Levetiracetam | 79 | suppressed |
| Linzess | Linaclotide | 77 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 77 | 19 |
| Valsartan | Valsartan | 77 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 73 | suppressed |
| Sucralfate | Sucralfate | 72 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 14 |
| Finasteride | Finasteride | 68 | suppressed |
| Mupirocin | Mupirocin | 67 | 38 |
| Myrbetriq | Mirabegron | 67 | suppressed |
| Methocarbamol | Methocarbamol | 65 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 18 |
| Anastrozole | Anastrozole | 62 | 12 |
| Azithromycin | Azithromycin | 61 | 50 |
| Rybelsus | Semaglutide | 60 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | suppressed |
| Baclofen | Baclofen | 56 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Mounjaro | Tirzepatide | 54 | 11 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Lidocaine | Lidocaine | 48 | 11 |
| Atenolol | Atenolol | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 21 |
| Azelastine Hcl | Azelastine Hcl | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 30 |
| Nystatin | Nystatin | 44 | 28 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 24 |
| Prazosin Hcl | Prazosin Hcl | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 22 |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Amoxicillin | Amoxicillin | 38 | 27 |
| Cephalexin | Cephalexin | 38 | 15 |
| Diazepam | Diazepam | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Trimethoprim | Trimethoprim | 38 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 19 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Nabumetone | Nabumetone | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 12 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Hydroxyurea | Hydroxyurea | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Trospium Chloride | Trospium Chloride | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 18 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Belbuca | Buprenorphine Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Klayesta | Nystatin | 19 | 12 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Multivitamin With Fluoride | Pedi Multivit No.17 W-Fluoride | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,824.15 · 158 records | Axsome Therapeutics, Inc. | ACCRUFER, AIRSUPRA, AQUACEL AG+ EXTRA, AREXVY, AZMIRO, Arikayce, Auvelity, BOTOX, BREZTRI, Belbuca, Brinsupri, CAPLYTA, CREON, DOVATO, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, INSPIRE, JARDIANCE, KISUNLA, Kimyrsa, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Orbactiv, Ozempic, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, QULIPTA, REPATHA, REXULTI, ROXYBOND, Rezzayo, Rybelsus, SHINGRIX, SMARTVEST, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, Tlando, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, XTAMPZA, XYOSTED, Xhance, YUPELRI, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error